USO 26017
Estudio abierto, aleatorizado y multicéntrico de fase III para evaluar la eficacia y la seguridad de BGB-43395 más letrozol frente a los inhibidores de CDK4/6 (abemaciclib, palbociclib y ribociclib) más letrozol en pacientes con cáncer de mama avanzado o metastásico HR+/HER2- que no hayan recibido previamente tratamiento anticanceroso sistémico para la enfermedad avanzada o metastásica
Tipos de enfermedades: Investigación sobre el cáncer de mama
Requisitos de elegibilidad:
• HR+/HER2-negative MBC (local testing)
• Archived FFPE tumor tissue submission required
• Must have measurable disease per RECIST v1.1. Bone-only disease
are eligible if BICR-confirmed evaluable with ≥ 1 lytic or mixed lyticblastic bone lesion (excluded: blastic-only metastases)
• Prior systemic tx in adv/met setting are excluded (except for <2 weeks
of NSAI monotherapy immediately preceding screening and
discontinued until study treatment initiation).
• Prior tx with ET ± CDK4/6i in the (neo)adjuvant setting with disease
recurrence <12 months after last dose of ET are excluded
• Prior tx selective CDK4 or CDK2 targeting agent, or any other
investigational anticancer drug in any setting are excluded
• Prior SERDs in adjuvant setting is allowed if disease recurrence
occurred >12 months after last dose of ET
• Untreated brain metastasis are excluded
Para más información sobre este juicio , HAGA CLIC AQUÍ.
Disponible en: